The largest and most up-to-date global vaccine safety study conducted has found a link between COVID-19 vaccines and heart, blood, and brain-related health issues. It is worth noting that this story, despite its controversial nature, was reported on by mainstream outlets such as Bloomberg and The New York Post, and the study was produced by a WHO-affiliated research network.

The conditions, termed “rare events,” include many phenomena noticed early on after the vaccine rollout, such as a higher risk for heart-related inflammation (myocarditis) caused by the mRNA vaccines made by Pfizer, BioNTech, and Moderna, and a higher risk of blood clots in the brain (cerebral venous sinus thrombosis, or CVST) from viral-vector vaccines made by AstraZeneca.

Another link was established between viral-vector vaccines and a neurological disorder called Guillain-Barre syndrome, in which the immune system short-circuits and attacks the body’s peripheral nervous system. This can lead to muscle weakness and even paralysis.

Learn the benefits of becoming a Valuetainment Member and subscribe today!

The Global COVID Vaccine Safety (GCoVS) Project was established in 2021 under the multinational Global Vaccine Data Network (GVDN). GVDN is an official member of the Vaccine Safety Net led by the World Health Organization (WHO).

This study, released in the journal “Vaccine” on February 12th, was conducted by over 30 researchers at ten sites in eight countries. It tested results from over 99 million individuals who had received roughly 240 million doses of the COVID vaccines.

Recipients of AstraZeneca were 6.9 times more likely to see swelling of the heart in a condition known as pericarditis; recipients of the first dose of Moderna were 1.7 times more likely and of the fourth dose 2.6 more likely.

Some 13.5 billion doses of COVID vaccines have been administered across the world since the shots were first made available.

Shane Devine is a writer covering politics, economics, and culture for Valuetainment. Follow Shane on X (Twitter).

Add comment